Overview

Pan Tumor Nivolumab Rollover Study

Status:
Recruiting
Trial end date:
2025-08-25
Target enrollment:
Participant gender:
Summary
Main Objective of this study is to examine long-term safety of nivolumab in participants on treatment and in follow up.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Nivolumab